Table 5.
Sensitivity results with the positive HIV-1/M samples (N = 225).
| Nbr of positive samples | EXACTO PRO TEST HIV | EZ-TRUST HIV 1 & 2 rapid screen test | Genie fast HIV1/2 | HIVTOP |
INSTI | STAT-VIEW HIV 1/2 | VIKIA HIV 1/2 | BioTechMed HIV1/2 Rapid-4b |
HIV combo |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | Ag | Ac | |||||||
| N = 100$ | 100 | 100 | 100 | 100 | 54 | 100 | 100 | 100 | 50 | 0 | 6 c | 100 |
| N = 125£ | 125 | 125 | 125 | 125 | 62 | 125 | 125 | 125 | 10 | 0 | 0 | 125 |
| Sensitivity | 100% | 100% | 100% | 100% | NA | 100% | 100% | 100% | 100% | NA | NA | 100% |
| 95% CI (%) | 97·9–100 | 97·9–100 | 97·9–100 | 97·9–100 | NA | 97·9–100 | 97·9–100 | 97·9–100 | 92·5–100 | NA | NA | 97·9–100 |
NA: not applicable.
Sensitivity was evaluated on 225 HIV-positive whole blood samples with seven 3G RSTs/STs (left part of the table) and two 4G RSTs/STs (right part of the table). For the HIV Combo (Alere) test, the detection of p24Ag is performed with a specific line, distinct from the antibody line. No antigen-specific line was present in the BioTechMed HIV1/2 Rapid-4 test. HIVTOP and BioTechMed HIV1/2 Rapid-4 are designed to discriminate HIV-1 from HIV-2 infections; results for both HIV-1 and HIV-2 are reported.
$
Corresponding to ART naive patients.
£
Corresponding to ART experienced patients.
b
N = 60.
c
Only 2/6 positive at 20 min.